dCROXI predicts clinical outcomes in patient with COVID-19 pneumonia treated with high-flow oxygen therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20221107004

Enrollment

Registered

2022-11-07

Start date

2022-11-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia Respiratory failure COVID-19 Pneumonia Respiratory failure High-flow oxygen therapy Weaning

Interventions

Patients with COVID-19 pneumonia confirmed by RT-PCR test and chest radiographic imaging, aged 18 years or more, and treated with HFNC.

Diagnostic

COVID-19 pneumonia

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or more, 2. Confirmed COVID-19 pneumonia by RT-PCR test and chest radiographic imaging, 3. HFNC treatment within 24 hours after admission

Exclusion criteria

Exclusion criteria: 1. No available data

Design outcomes

Primary

Measure	Time frame
Cutoff value of dCROXI for predicting the successful weaning from HFNC At 48 hours after admission Points	—

Secondary

Measure	Time frame
Prevalence of the successful weaning from HFNC At 2 weeks after admission percent	—

Countries

Thailand

Contacts

Public ContactNarongkorn Saiphoklang

Faculty of Medicine, Thammasat University

M_narongkorn@hotmail.com6629269794

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026